2Jarmay K, Karacsony G, Ozsvar Z, et al. Assessment of histological features in chronic hepatitis C. Hepatogastroenterology,2002, 49 : 239-43.
3Pockros PJ. Developments in the treatment of chronic hepatitis C. Expert Opin Investig Drugs, 2002, 11 : 515-28.
4Culver DH, Alter MJ, Mullan P,J, et al. Evaluation of the effectiveness of targeted lookback for HCV infection in the United States-interim results. Transfusion, 2000, 40:1176-81.
5Wang CS, Chang TT, Yao W J, et al. Comparison of hepatitis B virus and hepatitis C virus prevalence and risk factors in a community-based study. Am J Trop Med Hyg, 2002, 66(4):389- 93.
6Podzorski RP. Molecular testing in the diagnosis and management of hepatitis C virus infection. Arch Pathol Lab Med,2002, 126 : 285- 90.
7Jonas MM. Children with hepatitis C. Hepatology, 2002, 36(5Suppl 1) :S173-8.
8Azoicai D, Ivan A, Carasievici E, et al. The prevalence of the owner of serologic markers for the hepatitis C virus, in a north-eastern territory of Romania. Rev Med Chir Soc MedNat Iasi, 2001, 105(1) : 127-31.
9Nakayama E, Liu JH, Akiba T, et al. Low prevalence of anti-hepatitis C virus antibodies in female hemodialysis patients without blood transfusion:a multicenter analysis. J Med Virol,1996,48(3) : 284- 8.
10Fujiyama S, Tanaka M. Hepatitis C: epidemiology and therapy-with special reference to long-term prognosis after IFN therapy. Rinsho Byori, 2000, 48( 1 ) : 5-13.
